GCP
BCLI

GSA Capital Partners’s BRAINSTORM CELL THERAPUTC BCLI Stock Holding History

GSA Capital Partners’s Portfolio BCLI Stock Details BCLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-7,416
Closed -$63K – 1628
2024
Q1 		$63K Buy
+7,416
New +$40.8K 0.01% 1522
2021
Q4 		– Sell
-11,470
Closed -$568K – 1410
2021
Q3 		$568K Buy
11,470
+7,454
+186% +$392K 0.06% 629
2021
Q2 		$229K Buy
4,016
+2,326
+138% +$124K 0.03% 1117
2021
Q1 		$97K Buy
+1,690
New +$128K 0.02% 1003
2020
Q2 		– Sell
-833
Closed -$58K – 637
2020
Q1 		$58K Buy
+833
New +$65K 0.01% 948

Other funds holding BCLI

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
LWM
Liberty Wealth Management Oakland, California $800M AUM 20.44% 1-Year Est. Return
WCG
Weaver Consulting Group Huntington Beach, California $420M AUM 14.29% 1-Year Est. Return
AHB
Abner Herrman & Brock Jersey City, New Jersey $1.05B AUM 42.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

GSA Capital Partners's BCLI Position: Q2 2024 in Review

GSA Capital Partners sold out of BRAINSTORM CELL THERAPUTC (BCLI) in Q2 2024, closing a stake of 7,416 shares — an estimated $63K sold.

GSA Capital Partners first reported a position in BCLI in Q1 2020 and held it in 5 quarters. The position peaked at $568K in Q3 2021. 48 funds tracked by Wall St. Rank hold BCLI as of Q2 2024.

  • GSA Capital Partners reported no remaining BRAINSTORM CELL THERAPUTC position as of Q2 2024 after selling out during the quarter.
  • GSA Capital Partners sold 7,416 BRAINSTORM CELL THERAPUTC shares in Q2 2024, an estimated $63K.
  • GSA Capital Partners first reported a position in BRAINSTORM CELL THERAPUTC in Q1 2020 and held it in 5 quarters.
  • GSA Capital Partners's BRAINSTORM CELL THERAPUTC position peaked at $568K in Q3 2021.
  • 48 funds tracked by Wall St. Rank held BRAINSTORM CELL THERAPUTC as of Q2 2024.

Based on GSA Capital Partners's 13F filing for Q2 2024, filed 15 Aug 2024.